OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

COELIAC UK

(A Company Limited by Guarantee)

Registered Charity Number: 1048167 Registered Company Number: 03068044 Scottish Charity Number: SC039804

Amended

Page 1

Coeliac UK Annual Report and Financial Statements for the year ended 31 December 2023

Contents Page
Legal and administrative information 3-4
Structure, Governance and Management 5-8
Report of the Board of Trustees 9-19
Independent Auditors’ report 20-23
Consolidated statement of financial activities 24
Consolidated balance sheet 25
Consolidated statement of cash flows 26
Notes to the financial statements 27 - 44

Page 2

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Legal and administrative information

The organisation is a charitable company limited by guarantee, incorporated on 14 June 1995 and registered as a UK Charity on 20 July 1995. Coeliac UK is the successor organisation to The Coeliac Society which was established in 1968.

The Charity is governed by its Articles of Association which set out its objects and powers.

The Articles provide for the Board to consist of up to nine elected Trustees, two coopted Trustees and one Trustee nominated by the Health Advisory Council. A trustee shall hold office for a period of 3 years and shall then be subject to reelection and may be re-elected for a further term of 3 years after which they must retire as a Trustee but may be re-elected as a Trustee after an intervening period of at least 1 year.

Board of Trustees

Board of Trustees Lawrence Broadie Maureen Burnside – Chair (until 22/02/2024) Anne Davis (Appointed 3/08/2023) Kate Denham (Appointed 29/08/2023) Chris Dilloway – Chair (from 22/02/2024) Aishah Farooq Clive Hart (Appointed 18/04/2023) Angeli Hemnani (Resigned 29/08/2023) Kenneth O’Dea (Resigned 17/06/2023) Dr Anita Patel Professor Alan Perkins Dr Gerry Robins Reshma Shah (Resigned 17/06/2023) Miranda Sheffield (Appointed 31/08/2023) Nicola Valmas Company Secretary Ife Kantonna (Resigned 6/10/2023) Ashley Bailey (Appointed 22/02/2024) Chief Executive Hilary Croft Company number 03068044 Charity number 1048167 Scottish Charity number SC039804 Registered office and Artisan operation address Hillbottom Road High Wycombe Buckinghamshire HP12 4HJ

Page 3

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Auditors Moore Kingston Smith LLP
9 Appold Street
London
EC2A 2AP
Bankers HSBC Bank plc
Oxford Circus Branch
196 Oxford Street
London
W1D 1NT
Lloyds Bank
21-31 White Hart Street
High Wycombe
Buckinghamshire
HP11 2HL
Investment manager Cazenove Capital
1 London Wall Place
London
EC2Y 5AU
Solicitors Blaser Mills
Park House
40 Oxford Road
High Wycombe
Buckinghamshire
HP11 2EE

Page 4

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

The Charity

Structure, Governance and Management

Coeliac UK is a charitable company limited by guarantee, incorporated on 14 June 1995, and registered as a Charity on 20 July 1995 with the Charity Commission. It was also registered with the Office of the Scottish Charity Regulator in 2008.

The Charity’s objectives are set out in its Articles of Association adopted on 3rd July 2021:

Public Benefit

The Trustees, in exercising their powers and duties, have complied with their duty in Section 17 of the Charity Act 2011 to have due regard to the public benefit guidance published by the Charity Commission. In preparing the report and accounts, the Trustees complied with the requirements in that guidance to report on the significant activities and achievements of the Charity in 2023. They have reported in a way that both sets out the aims and strategies of the Charity and demonstrates how the aims and activities of the Charity were carried out for the public benefit.

Management and staff

The Board of Trustees delegates the day-to-day management of the Charity to the Chief Executive who led a team of approximately 52 full time equivalent staff in 2023. Their work is supplemented at times of peak workload by a limited number of temporary staff. The staff work within the Delegation of Authority agreed by the Board. The staff agree a work plan with the Board at the beginning of the year and report progress at Board meetings throughout the year, through quarterly reporting.

The Board of Trustees appoints an HR Committee to oversee the setting of pay and remuneration for senior management and the entire organisation. Their remit is to regularly review and agree performance review arrangements; agree remuneration policies including terms, conditions and benefits; consider recommendations for individual pay on the basis of individual appraisals and to consider the Charity’s human resource strategy. The committee comprises the Chair of the Board of Trustees and at least two other Trustees.

The organisation is comprised of Coeliac UK, a registered Charity, and its subsidiary The Coeliac Trading Company Ltd. The principal activity of the trading subsidiary is to raise funds on a commercial basis for the Charity to support its charitable activities. The subsidiary is governed by two directors appointed from the senior management team of the Charity, one Trustee from the Board of the Charity, and chaired by an independent director.

In December 2023, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK. Following the transfer, The Coeliac Trading Company Ltd became dormant and ceased to trade.

Page 5

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

The Board of Trustees

The Board of Trustees lead the Charity in setting its strategic direction and agreeing objectives and plans to deliver the Charity’s aims. The Board monitors and evaluates the progress of the Charity to ensure it achieves those objectives and plans.

The expertise within the Board is substantial, wide-ranging and importantly complementary. Trustees include director-level individuals from finance, fundraising, HR, marketing, law and healthcare backgrounds. All Trustees are volunteers committing many hours to the work of the Charity.

The Board’s Committees/Councils

The Board delegates some of its responsibilities to specialist groups to provide particular focus and expertise on key issues and opportunities:

Audit Committee

Ensures the robustness of the Board’s overall financial and risk monitoring. The role of the Committee is to support the Board of Trustees in monitoring the adequacy of the Coeliac UK’s corporate governance and control systems by offering objective advice on issues concerning the risk, control and governance of the organisation and associated assurances provided by external audit and other processes. It ensures the Charity’s financial management meets the standards of good practice accepted by the Charity Commission and Companies House.

People Committee (see Management and staff above)

Oversees the Charity’s HR policies ensuring they are legally compliant and fit for purpose.

Executive Action Committee

Allows the Board to retain control in crisis situations when the full Board may not be able to be convened. The Committee would only be called upon in emergencies and was not invoked in 2022.

Health Advisory Council (HAC)

Brings expert insight into health issues related to coeliac disease, associated research and advice on related policies and activities. The Council draws upon a wide range of expertise to reflect all aspects of healthcare and includes representation from across all four UK nations.

Food Standards Committee (FSC)

Provides the Charity with additional technical expertise and independent appraisal of the standards applied to its licensing and accreditation activities. It also engages with other industry and regulatory bodies to ensure the exchange of ideas and state of the art information.

Page 6

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Research Strategy Board (RSB)

In addition to bringing expert knowledge and experience, the RSB fulfils governance requirements for the review and development of the Charity’s research strategy which underpins the Charity’s Research Fund.

Research Awards Panel (RAP)

Manages the awards process for grants under the Research Fund. It provides the Charity with expert insight and fulfils governance requirements for the review, funding and management of the Charity’s research awards in line with the Charity’s Research Strategy. The Panel reports to the Board of Trustees.

Fundraising Committee

Brings the Charity expert insight and fulfils the governance requirements for the detailed scrutiny and oversight of the fundraising undertaken for the Charity including for the Research Fund.

Commercial Committee

Provides the Charity expert insight to help plan the Commercial Services strategy and deliver its activities.

Board of the Trading Company

During the year, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK, and the Directors of the subsidiary have decided that the company shall remain dormant for the foreseeable future.

Meeting protocol

The Boards and committees continued to use a combination of face-to-face meetings, video calls and teleconferences during the year to review plans and activities of the Charity and ensure the cost effectiveness of their operations.

Recruiting and supporting Trustees

The Board of Trustees regularly undertakes an audit to identify current and future skills gaps. Roles are advertised widely both in the Charity’s communications to members and on recruitment websites open to all. The selection process comprises shortlisting based on CVs and supporting statements, followed by an interview panel for shortlisted candidates. Following appointment, new Trustees are provided with induction packs, formal training as required for the role, and sessions spent with key staff.

Our approach to Fundraising

As a charity registered with the Fundraising Regulator, we strive to achieve the highest standards in all our fundraising activities, referring to all relevant professional and statutory bodies as guidance and regulation develops. Our aim to develop positive long-term relationships with our members, donors and supporters underpins all our actions in this area.

Coeliac UK operates with a small team of in-house staff to lead and develop its fundraising. Fundraising staff are expected to act professionally at all times, follow the Fundraising Regulator’s Code of Conduct and are encouraged to undertake training to develop their knowledge. Fundraising staff receive a salary but are not eligible for a performance bonus.

Page 7

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

We also use the services of several carefully selected external companies who provide specialist skills to help us deliver specific activities. These include a telephone agency, as well as a raffle and lottery manager. With each of these companies, we have signed agreements, committing them to adhere to both the letter and spirit of the regulations.

Any complaints that fundraising activity may generate are recorded and investigated by the appropriate line manager to ensure future learning opportunities in fundraising. Coeliac UK is pleased that its fundraising activity generates few complaints annually. In 2023, we received 4 complaints, 3 of which related to our external partners, and one of which related to frequency of contact from the Charity. All complaints were quickly resolved without escalation.

Managing risk

The Trustees are responsible for ensuring appropriate financial and other controls are in place. At Coeliac UK, the role of risk management is delegated to the Audit Committee who review the risk quarterly and report back to the full Board.

A risk register is used by the Board and staff to review the main risks and uncertainties, and systems put in place for management and mitigation. The register is regularly updated and monitored by the executive team and Board as work progresses through the year.

The key risks are made up of financial, operational, regulatory, external and strategic risks; and the main residual high risk identified (after mitigating actions) in 2023 was that income raised from all fundraising channels does not meet the budget target for net income.

Page 8

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Report of the Board of Trustees

The Board of Trustees who are the Charity Trustees, and Directors of Coeliac UK (‘the charitable company’/’the Charity’), have pleasure in presenting their report, which incorporates the report of the Directors for the purposes of company law, and the accounts for the year ended 31 December 2023.

Amended financial statements

These financial statements have been amended from those previously approved by the Trustees on 16 April 2024. Expenditure has been reclassified to correctly represent the activity in the year. These amended financial statements:

Introduction

2023 saw Coeliac UK return to growth in many areas. Our membership has returned to postpandemic levels and is on an upward trajectory; more people know about us; satisfaction with our services is higher than ever; we have re-engaged with researchers to advance our “journey to a cure”; and our overall audience is growing and becoming more engaged. Our financial position remains strong, and we finished the year ahead of where we expected.

This is a very good position for us to be in as we enter 2024.

All this has happened despite some significant operational challenges, including a relatively high level of staff turnover and consequently many gaps in resource, ongoing systems migrations, and the upheaval of our move to a new office, although much better suited to our needs.

We are grateful to all our staff, volunteers, supporters, partners, and donors, who help us to do our important work every day. With the NHS in crisis, Coeliac UK really is the place where people with coeliac disease and those needing to live without gluten can turn to for help. We know people value our work, and we continue to be ambitious to reach more people and deliver even better support and outcomes for our community. We provide vital services and information to support those diagnosed or caring for someone with coeliac disease in living a gluten free life and guidance and advice to those seeking diagnosis. We also lead the campaigning alongside the health and food sectors to educate and raise awareness to increase understanding of the condition and the treatment required. With growing support, in the longer term, we will continue to fund research to improve management of the condition, the development of treatments and ultimately a cure.

From initial diagnosis Coeliac UK provided the explanation as to what’s happening and lots of supportive information on how to manage the gluten free diet and eating out … the information was there to inform choices. I hope Coeliac UK can continue to grow and support other sufferers. Keith, York

Page 9

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Our major achievements for 2023 included:

Key Activities for 2023

Objectives and activities delivered in 2023 continued to align with the 2020-2025 strategic themes. Some highlights include:

Reach

Page 10

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Coeliac UK helped me to manage my condition, and it’s reassuring to know I am not alone, have a point of reference and can seek answers, recipes, and direction when necessary. Roger, Bexhill on Sea

Research

Page 11

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Experience

Our work in Devolved Nations

Coeliac UK is a national organisation with an international reach. In the UK, we are committed to supporting needs of our community wherever they reside and recognise there are differences in each of the UK’s nations in terms of government, health policy and practice, and community priorities. In 2023, we continued to build on our work supporting people with Coeliac disease in the UK’s devolved nations as follows:

Page 12

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

It's important to me that there is an organisation dedicated to helping those with coeliac disease and raising awareness about this condition. It's important that I don't feel alone struggling with Coeliac disease and I have support from other people. Alyson, Sandhurst

Partnerships

Working with Coeliac UK has given us the opportunity to critically look at our allergy process as a whole and GF menu options. Whilst Bill’s has had an “Avoiding Gluten” Menu for many years it is great that we can now offer our guests a “Gluten Free” menu with confidence that our systems and processes are in line with Coeliac UK standards, giving our guests more choice and confidence. In addition to this the accreditation has allowed us to join the Coeliac UK network, bringing Bill’s to Coeliacs across the UK. Eunan – Health and Safety Manager for Bills

Global Leadership

Page 13

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Information from Coeliac UK has helped me understand my symptoms. I suffered from unexplained anaemia, headaches, and bone pain. I was unaware these were symptoms of coeliac disease. Fortunately, my GP was aware which led to diagnosis. The food label scanner is extremely useful, and I use it all the time. Carolyn, Dalbeattie

Plans for 2024

2024 sees the last year of our current five-year strategy. This year we plan to review and update our strategy starting with renewing and strengthening our overall proposition. This will ensure that we continue to focus on the things that will deliver the outcomes most valued by our beneficiaries. We will consult with those that we currently impact, as well as those not currently engaged with us, to help us think widely about where we focus, in addition to the existing insight we have gathered on what people value in our work. We are excited to see where this takes us and see this as an opportunity to reflect on what we deliver for our community is a post-covid/cost of living crisis world. We still see significant opportunities for extending our reach and service offering, bringing real benefits to the community, and want to re-ignite our commitment to delivering this through the lens of an updated strategy.

Alongside the proposition and strategy work, the Charity will continue to focus on delivering objectives that are aligned with our current strategic themes - in addition to “business as usual” activity, we have the following plans:-

Reach

Page 14

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Research

Experience

Page 15

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

Partnerships

Global Leadership

Financial Review

Overview

The Charity has three main sources of funding: membership fees, commercial services our restaurant accreditation scheme and licensing of the Crossed Grain Trademark), and fundraising from donations (including from gifts in wills). We also raise money through our raffles and lottery, and through grant income.

These funds enable us to provide services and information to support those diagnosed or caring for someone with coeliac disease in living a gluten free life and in providing guidance and advice to those seeking diagnosis. We are actively engaged in campaigning with the health and food sectors to educate and raise awareness to increase understanding of the condition and the treatment required. In the longer term, these income streams enable the Charity to fund research to improve management of the condition, the development of treatments and ultimately a cure.

The Charity’s total income in 2023 was £4.2m, an increase of £0.1m from £4.1m income in 2022. Income from trading activities and charitable activities fell slightly from £2.5m in 2022, to £2.4m in 2023. The income from donations and legacy increased to £1.7m, £0.1m higher than gifts received in 2022; we also raised a further £0.5m from other sources, including the raffle and lottery. Following the cautious re-entry to the investment markets in 2022, investment income benefitted from a full year in the market generating £65k in 2023 up from £17k in 2022.

Expenditure in 2023 increased to £4.1m, £0.6m more than the £3.5m spend in 2022, primarily reflecting an increase in our investment in research. We have also invested in the organisation, especially our Commercial Services team as we seek to develop more relationships with licensed retailers and restaurants providing wider choice to those living with Coeliac disease.

Page 16

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

As a result of the above, overall, the Charity achieved a net surplus of £119k for 2023. We are pleased with this better than budgeted performance; we had planned for 2023 to be another year of consolidation as the Charity continues the slow journey of re-building after the extended impact of Covid, and investment in the organisation as we make the Charity fit for the future.

Following a small loss of £16k in 2022, our investment assets rebounded slightly in 2023, generating a small gain of £24k.

Our focus in 2024 will be on continuing to develop a portfolio of sustainable income streams, and careful management of expenditure, to ensure that we achieve a good return on investment for our members and supporters and deliver improving outcomes for our beneficiaries.

Investing in research

We are pleased to report that our total research expenditure during the year increased significantly from £135k to £275k, over 6% of income. We had planned to make a further award, but due to unforeseen circumstances this slipped in to early 2024. Added to the further awards planned, 2024 will likely see our largest ever research spends.

Investment policy and Performance

The Charity’s investments are managed by Cazenove Capital, to provide a reasonable and growing income over the long term, commensurate with a moderate but not excessive degree of risk. The Charity will not invest in high risk instruments, such as derivatives, hedge funds, covered warrants or spread betting.

In August 2022, the Charity cautiously invested £340K in the Charity Responsible Multi-Asset Fund managed by Cazenove. This was following the divestment of the surplus cash held in the Cazenove multi asset fund in 2020, to safeguard the charities assets and restricted funds due to the volatility the stock market experienced during the COVID pandemic.

During 2023, we moved the remaining £623k funds from the Cazenove Cash Account to the Charity Responsible Multi-Asset Fund, ending the year with total investments of £983k.

Most of the remaining cash balance is held in our HSBC accounts, £600k of which was invested in short-term money-market accounts, and the balance in overnight higher interest accounts to get a better return.

Bank interest received from our cash deposits in 2023 was over £40k which compares favourably with the £15k achieved in 2022. We also received investment income, in the form of dividends, to the value of £24k compared with just £2k in the prior year.

The Charity regularly reviews its cash and investment position and subject to ongoing liquidity requirements will consider further investment in 2024.

Reserves policy

The Board recognises the need to hold charitable funds as free reserves to safeguard the continuity of provision of basic services, to fund periods of expenditure in excess of revenue and to fund unexpected expenditure.

As part of the 2023 year-end review process, the Board of Trustees used Charity Commission guidelines to update the reserves policy.

The Board agreed to a policy that sufficient reserves will be held to ensure the Charity can continue to operate and meet its charitable commitments, should there be a time when

Page 17

Annual Report and Financial Statements for the year ended 31 December 2023

Coeliac UK

income has been adversely impacted. This is to allow time to assess and implement the future options for the Charity. Excess reserves will be designated for a specific activity when an appropriate and timely use of the funds has been identified and agreed by the Board. In the event there are no extra reserves, the Board may utilise the operational reserves to meet any of the above needs should they arise, subject to a cost benefit analysis.

The target level of reserves as at 31st December 2023 has been calculated at £810k, being the mid-point within the range £640k to £980k. The Reserves target is calculated by assuming an average reduction in forecast income of 24% offset by a forecast reduction in discretionary costs, equal to a reduction in total costs of approximately 7.5%. We ended the year with unrestricted reserves of £1,633k, some £800k above the target. These surplus reserves will be reinvested in our charitable activities over the next strategic period, increasing our support to those living with Coeliac disease.

The Board also wish to maintain a level of liquid reserves that ensures the Charity is able to meets its obligations as they fall due. The level of liquid reserves required and liquid reserves available is reviewed regularly throughout the year. As at 31st December 2023, the Charity had £2.25m in liquid assets (cash and other liquid investments).

Of our restricted reserves of £571k, we had £492k held for our Research Fund. Sometimes, we raise funds solely for research to build a sufficient sum to launch a research call for grant applications. In 2023 we put out a new research call to the value of up to £250k. The grant award will be made for research commencing in 2024. Of our designated reserves, £12k is held for research projects, while £81k is funds for our local voluntary support groups allowing groups to actively provide support to members in their local area.

Responsibilities of the Board of Trustees

The Board of Trustees (who are also directors of Coeliac UK for the purposes of company law) is responsible for preparing the Report of Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board of Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

Page 18

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

The Board of Trustees is responsible for keeping adequate accounting records which are sufficient to show and explain the charitable company’s transactions and which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the Charitable Company’s constitution. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the Board of Trustees are aware:

The Board of Trustees is responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the Special Provisions of Part 15 of the Companies Act 2006 relating to Small Companies.

This report was approved and authorised for issue by the Board of Trustees on 16th April 2024 and signed on their behalf by

Chris Dilloway

Chair

Registered Company Number: 03068044

On diagnosis I felt I had been shut in a long dark tunnel. But with all the help and regular emails, recipes, and the magazine dropping through the door. I could see a light at the end of the tunnel, and I don’t feel alone - there’s someone who understands. Thank you, Coeliac UK. Susan Norwich

Page 19

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

Opinion

We have audited the amended financial statements of Coeliac UK (the parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2023 which comprise the group statement of financial activities, group and parent charity balance sheet and group statement of cash flows and notes to the amended financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). These amended financial statements replace the original financial statements approved by the trustees on 16 April 2024.

The amended financial statements have been prepared in accordance with The Companies (Revision of Defective Accounts and Reports) Regulations 2008 and as such do not consider events which have taken place after the date on which the original financial statements were approved.

In our opinion the amended financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the amended financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Emphasis of matter - Amendment of expenditure classification

We draw attention to note 1 of the amended financial statements, which describes why amended accounts have been issued. Our opinion is not modified in this respect.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of of assurance conclusion thereon.

Page 20

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact.

We have nothing to report in this regard.

Other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Board of Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the Statement of Responsibilities of the Board of Trustees set out on page 15, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under the Companies Act 2006 and under the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Page 21

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

Page 22

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of noncompliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members and trustees as a body, for our audit work, for this report, or for the opinions we have formed.

3 September 2024 James Saunders (Senior Statutory Auditor) Moore Kingston Smith LLP Statutory Auditors 9 Appold Street London EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

Page 23

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Consolidated statement of financial activities (including consolidated income and expenditure account)

Notes
Income
Donations and legacies
2
Income from charitable activities
2
Income from trading activities
2
Investment income
2
Total income
Expenditure
Expenditure on raising funds
Donations and legacies
Trading activities
Expenditure on charitable activities
3
Other expenditure
Total expenditure
Net gains/(losses) on investments
11
Net income/(expenditure)for the year
7
Balances brought forward
Total funds carried forward		 Unrestricted funds
Restricted funds
2023
Total
2022
Total
(£)
(£)
(£)
(£)
1,611,891
125,728
1,737,619
1,566,102
1,946,197
35,475
1,981,672
2,032,931
466,739
-
466,739
438,473
64,999
-
64,999
16,933
4,089,826
161,203
4,251,029
4,054,439
370,365
-
370,365
241,092
423,947
-
423,947
326,531
3,171,155
156,374
3,327,529
2,923,831
-
-
-
24,158
3,965,467
156,374
4,121,841
3,515,612
24,798
(851)
23,947
(16,152)
149,157
3,978
153,135
522,675
2,036,718
566,855
2,603,573
2,080,898
2,185,875
570,833
2,756,708
2,603,573

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 27 to 44 form part of these financial statements.

Page 24

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Consolidated balance sheet

GROUP CHARITY
Notes 2023 2022 2023 2022
£ £ £ £
FIXED ASSETS
Tangible assets 10 156,996 28,568 156,996 105,264
Intangible Assets 10 115,172 105,264 115,172 28,568
Investments 11 982,580 323,848 982,582 323,850
1,254,748 457,680 1,254,750 457,682
CURRENT ASSETS
Investment & deposits 11 - 623,357 - 623,357
Debtors 12 1,604,690 1,008,099 1,716,594 1,211,568
Cash at Bank 1,269,542 1,692,267 1,157,636 1,431,807
2,874,232 3,323,723 2,874,230 3,266,732
CURRENT LIABILITIES
Creditors - falling due within one year 13 (1,372,272) (1,137,830) (1,372,272) (1,080,839)
NET CURRENT ASSETS 1,501,960 2,185,893 1,501,958 2,185,893
Total assets plus current liabilities 2,756,708 2,643,573 2,756,708 2,643,575
Provisions for liabilities and charges 14 - (40,000) - (40,000)
NET ASSETS 2,756,708 2,603,573 2,756,708 2,603,575
The funds of thecharity
Unrestricted funds
Designated 15 93,223 98,291 93,223 98,291
General 2,092,651 1,938,427 2,092,651 1,938,429
2,185,875 2,036,718 2,185,875 2,036,720
Restricted funds 16 570,833 566,855 570,833 566,855
Total charity funds 2,756,708 2,603,573 2,756,708 2,603,575

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011. These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

As permitted by s408 Companies Act 2006, the parent charity has not presented its own Statement of Financial Activity and related notes. The parent charity's profit for the year was £153,136 (2022: £522,675).

Approved by the Board of Trustees and authorised for issue on__these financial statements are signed on 03/09/24 their behalf by:

Chris Dilloway - Chair

Company number: 03068044

The notes on pages 27 to 44 form part of these financial statements.

Page 25

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Consolidated statement of cash flows
Notes
Cash flows from operating activities:
Net cash provided by operating activities
22
Cash flows from investing activities:
Dividends, interest and rents from investments
Bank interest
Purchase of tangible fixed assets
Purchase of investments
Net cash used in investing activities
Increase in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
22
Total Cash and cash equivalents at the end of the year
22		 2023
£
(270,481)
24,454
40,545
(205,816)
(634,783)
(775,600)
(1,046,081)
2,315,623
1,269,542		 2022
£
(119)
2,099
14,833
(133,980)
(340,000)
(457,048)
(457,167)
2,772,790
2,315,623

Page 26

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

1 ACCOUNTING POLICIES

1.1 Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK (FRS102) and Charities SORP (FRS 102) and the Companies Act 2006.

Coeliac UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

There are no material uncertainties about the charity's ability to continue as a going concern. The charity's planned activities, together with its financial position; management of risk and approaches to investments, cashflow and reserves are described in the Report of the Board of Trustees. As a consequence, the Trustees believe that the charity is well placed to manage its risks successfully despite the current uncertain economic outlook. The Trustees have a reasonable expectation that the charity and the group have adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.

1.2 Local groups and accounting policy

The local groups record their income and expenditure on a receipt basis. At the end of the financial year, each group submits a return of its income and expenditure which is included in the Statement of Financial Activities and the Balance Sheet.

1.3 Income

Income from web advertising, sponsorship and licensing, and accreditation is deferred on a proportionate basis over the life of the contract. All other income is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and legacies includes donations and gifts, legacies, and all other income that is in substance a gift made on a voluntary basis. It also includes grants of a general nature provided by government and charitable foundations which are not conditional on delivery of certain levels or volumes of a service The donation may be made towards the general aims of Coeliac UK (unrestricted), or towards a specific service or aim (restricted). Donations are recognised on receipt of the donation, or if earlier, at the point where there is a written obligation for a donor to pay a specified donation. Legacies are recognised at the point entitlement is established, receipt is considered probable and the estate value can be estimated reliably.

1.4 Cost allocation

Shared costs have been allocated on the following basis:

Description Method of apportionment Depreciation Head count Information technology Head count Support staff costs Head count Office costs Head count

Page 27

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

1 ACCOUNTING POLICIES (Continued)

1.5 Grants

Grants payable are payments made to third parties in furtherance of the charitable objectives.

Grants which are free from specific conditions are recognised in full as soon as there is a legal or constructive obligation committing the charity.

Multiyear grants are conditional on an annual review of progress which will determine if future funding is provided. Due to this condition only one year's funding commitment is recognised.

1.6 Restricted funds

Restricted funds are to be used for specific purposes as specified by the donor. Expenditure which meets these criteria is charged to the fund.

1.7 Depreciation of fixed assets

Provision is made for depreciation on all tangible assets at rates calculated to write off the cost, less estimated residual value of each asset over its expected useful life, as follows:

Furniture and fittings 20% p.a. straight line Computer equipment 33.33% p.a. straight line

1.8 Investments

Investments held as fixed assets are revalued at mid-market value at the balance sheet date.

1.9 Leasing

Rental payable under operating leases are charged against income on a straight-line basis over the lease term.

1.10 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of obligation can be measured reliably. Costs are analysed between expenditure on charitable activities and costs of raising funds of the charity.

Any direct costs are allocated between restricted and unrestricted funds as incurred.

1.11 Designated funds

Designated funds are unrestricted funds earmarked by the board of Trustees for particular purpose.

1.12 Pension

The charitable company operates a group personal money purchase pension scheme. The pension cost charged in the financial statements represents contributions payable by the charity during the financial year.

1.13 Basis of consolidation

The group accounts consolidate the accounts of Coeliac UK and its subsidiary undertaking on a line by line basis. The accounts are made up to 31 December 2023. No separate statement of financial activities or income and expenditure has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

1.14 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.15 Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

1.16 Amended financial statements

These financial statements replace the financial statements originally approved by trustees on 16 April 2024. Expenditure has been reclassified to correctly represent the activity in the year. The amendment relates to expenditure on raising funds, trading activities and expenditure on charitable activities as set out in notes 3 to 5 of the financial statements.

Page 28

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

2
INCOME
Income from donations and legacies
Donations and gifts
Legacies
Income from charitable activities
Membership
Raising Awareness
Research
Groups
Income from trading activities
Raffle and lottery
Other commercial activities
Investment Income
Investments - dividends
Bank interest		 Unrestricted
647,668
964,223
1,611,891
1,129,754
812,281
-
4,162
1,946,197
443,732
23,007
466,739
24,454
40,545
64,999
4,089,826		 Restricted
£
120,728
5,000
125,728
-
35,475
-
-
35,475
-
-
-
-
-
-
161,203		 2023
Total
£
768,396
969,223
1,737,619
1,129,754
847,756
-
4,162
1,981,672
443,732
23,007
466,739
24,454
40,545
64,999
4,251,029

Page 29

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

2
INCOME (continued)
Income from donations and legacies
Donations and gifts
Legacies
Income from charitable activities
Membership
Raising Awareness
Research
Groups
Income from trading activities
Raffle and lottery
Other commercial activities
Investment Income
Investments - dividends
Bank interest		 Unrestricted
631,181
708,235
1,339,416
1,180,435
792,249
-
32,469
2,005,153
426,038
11,357
437,395
2,099
11,819
13,918		 Restricted
£
186,659
40,027
226,686
-
27,778
-
-
27,778
-
1,078
1,078
-
3,015
3,015		 2022
Total
£
817,840
748,262
1,566,102
1,180,435
820,027
-
32,469
2,032,931
426,038
12,435
438,473
2,099
14,834
16,933

Page 30

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

3
Expenditure
Charitable activities
Membership
Raising Awareness
Research
Groups
International
Breakdown of costs of charitable activities
Membership
Raising Awareness
Research
Groups
International
Research cost breakdown
Direct Research costs
Support costs (Note 5)		 Direct costs
1,004,387
1,261,025
172,228
95,548
-
2,533,188		 Unrestricted
£
1,307,322
1,476,870
248,927
138,036
-
3,171,155
Grants made
(notes 6)
-
-
30,000
-
-
30,000
Direct costs
172,228
16,555
188,783		 Restricted
£
-
122,143
34,231
-
-
156,374
Support costs
(note 4, 5)
302,935
337,988
80,930
42,488
-
764,341
Grants made
30,000
64,375
94,375		 2023
Total
£
1,307,322
1,599,013
283,158
138,036
-
3,327,529
2023
Total
1,307,322
1,599,013
283,158
138,036
-
3,327,529
2023
202,228
80,930
283,158

All support costs are allocated on a headcount basis.

Page 31

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

3
Expenditure (continued)
Charitable activities
Membership
Raising Awareness
Research
Groups
Breakdown of costs of charitable activities
Membership
Raising Awareness
Research
Groups
Research cost breakdown
Direct Research costs
Support costs		 Direct costs
841,279
1,075,455
90,754
98,281
2,105,769		 Unrestricted
£
1,147,572
1,380,566
135,272
149,742
2,813,152
Grants made
(notes 6)
-
-
-
-
-
Direct costs
95,596
6,131
101,727		 Restricted
£
-
110,679
-
-
110,679
Support costs
(note 4 ,5)
306,293
415,790
44,518
51,461
818,062
Grants made
-
38,387
38,387		 2022
Total
£
1,147,572
1,491,245
135,272
149,742
2,923,831
2022
Total
1,147,572
1,491,245
135,272
149,742
2,923,831
2022
95,596
44,518
140,114

All support costs are allocated on a headcount basis.

Page 32

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

4
Total support cost breakdown by activity
Cost of raising funds
Donations and legacies
Trading activities
Charitable activities (note 3)
Cost of raising funds
Donations and legacies
Trading activities
Charitable activities (note 3)		 Staff costs
£
22,185
16,964
201,843
240,992
Staff costs
£
25,154
22,542
330,713
378,409		 Other costs
£
61,827
47,273
562,498
671,598
Other costs
£
37,510
33,615
493,156
564,281		 2023
Total
£
84,012
64,237
764,341
912,590
2022
Total
£
62,664
56,157
823,869
942,690

Page 33

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

5
Support cost apportionment
Expenditure on raising funds
Donations and legacies
Trading activities
Charitable activities
Membership
Raising awareness
Research
Groups
Expenditure on raising funds
Donations and legacies
Trading activities
Charitable activities
Membership
Raising awareness
Research
Groups		 Support staff
22,185
16,964
79,998
89,254
21,371
11,220
240,992
Support staff
25,154
22,542
123,823
168,089
17,997
20,804
378,409		 Depreciation
5,329
4,075
19,216
21,440
5,134
2,695
57,889
Depreciation
2,832
2,538
13,942
18,926
2,026
2,342
42,606		 Governance
2,655
2,029
9,572
10,680
2,557
1,343
28,836
Governance
1,844
1,652
9,076
12,320
1,319
1,525
27,736		 HR costs
5,905
4,515
21,292
23,755
5,688
2,986
64,141
HR costs
4,847
4,344
23,861
32,391
3,468
4,009
72,920		 IT costs
£
19,192
14,675
69,203
77,211
18,488
9,706
208,475
IT costs
£
8,951
8,021
44,060
59,811
6,404
7,403
134,650		 Office costs
£
28,746
21,979
103,654
115,648
27,692
14,538
312,257
Office costs
£
19,036
17,059
93,706
127,203
13,620
15,744
286,369		 2023
Total
£
84,012
64,237
302,935
337,988
80,930
42,488
912,590
2022
Total
£
62,664
56,156
308,468
418,740
44,834
51,828
942,690

Page 34

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

6 Grants payable

Grants payable
Children and Young people's grant 2023
2022
£
£
30,000
-
30,000
-
Grants to institutions
-

In accordance with the accounting policy outlined in note 1.5, only the first year of funding commitment is recognised on the accounts for multiyear grants which are conditional on an annual review of progress which determines if future funding is provided.

7 Net incoming (outgoing) resources for the year

This is stated after charging

Depreciation and amortisation
Operating lease rentals
Trustees liability insurance
Audit services
Non - audit services provided by the auditor
General advice
Tax compliance		 2023
£
66,866
72,412
1,100
15,835
2,085
895
159,193		 2022
£
46,495
73,049
1,100
13,575
1,975
845
137,039

Travel costs amounting to £1,316 (2022 - £1,291) were reimbursed to 4 (2022 - 4) members of the Board of Trustees.

8 Staff costs and numbers

Staff costs and numbers
Salaries and wages
Social security costs
Pension costs		 2023
£
1,860,552
192,822
98,961
2,152,335		 2022
£
1,527,899
162,417
81,842
1,772,158

Page 35

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

The number of employees whose salary amounted to over £60,000 during:

2023 2022
Number Number
£60,000 - £70,000 4 -
£70,000 - £80,000 - -
£80,000 - £90,000 - 1
£90,000 - £100,000 - -
£100,000 - £110,000 1 -

The key management personnel of the group (and charity) comprise the Trustees, the chief executive and senior management team. The total employee benefits ( Salary, Employers National insurance and Employers pension) of the key management personnel of the group were £652,893 (2022: £350,825). None of the Trustees have been paid any remuneration or received any benefits for performing their role as Trustee of the charity.

No termination payments for payments in lieu of notice (PILON) were paid in the year (2022: £10,414).

The average monthly number of employees during the year, calculated on the basis of average headcount was as follows:

Advice and information
Administration and support		 2023
2022
Number
Number
43
39
9
7
52
46

9 Taxation

The charitable company is exempt from Corporation Tax on its charitable activities under Sections 466 to 493 of the Corporation Tax Act 2010.

10 Fixed assets - Group

Cost
At 1 January 2023
Additions
Disposals
At 31 December 2023
Amortisation and depreciation
At 1 January 2023
Charge for the year
Eliminated on disposal
At 31 December 2023
Net book values
At 31 December 2023
At 31 December 2022		 Intangible
Assets
£
297,172
54,010
(172,082)
179,100
191,908
55,811
(183,791)
63,928
115,172
105,264		 Furniture &
Computer
fittings
equipment
Total
£
£
£
152,592
552,440
705,032
141,000
10,806
151,806
(152,592)
(531,841)
(684,433)
141,000
31,405
172,405
151,981
524,483
676,464
-
11,055
11,055
(151,981)
(520,129)
(672,110)
-
15,409
15,409
141,000
15,996
156,996
611
27,957
28,568

Page 36

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

10 Fixed assets - Charity

Cost
At 1 January 2023
Additions
Disposals
Impairment
At 31 December 2023
Amortisation and depreciation
At 1 January 2023
Charge for the year
Eliminated on disposal
At 31 December 2023
Net book values
At 31 December 2023
At 31 December 2022
Fixed asset investments - Group And Charity
Market Value at 1 January
Additions
Disposals
Realised investment gains/(losses)
Market Value at 31 December
Historical cost as at 31 December 2023		 (Charity only)
Investments in
subsidiaries
£
2
-
-
-		 Intangible
Assets
£
297,172
167,808
(172,082)
(113,798)
179,100
191,908
55,811
(183,791)
63,928
115,172
105,264
Unit trusts
£
323,848
634,783
-
23,947
982,578
974,783		 Furniture &
Computer
fittings
equipment
Total
£
£
£
152,592
552,440
705,032
141,000
10,806
151,806
(152,592)
(531,841)
(684,433)
-
-
-		 Furniture &
Computer
fittings
equipment
Total
£
£
£
152,592
552,440
705,032
141,000
10,806
151,806
(152,592)
(531,841)
(684,433)
-
-
-
141,000
31,405
172,405
151,981
524,483
676,464
-
(8,556)
(8,556)
(151,981)
(500,517)
(652,498)
-
15,410		 15,410
141,000
15,995
611
27,957
Total
2023
£
323,850
634,783
-
23,947
982,580
974,785		 156,995
28,568
Total
2022
£
2
340,000
-
(16,152)
2 323,850
2 340,002

11 Fixed asset investments - Group And Charity

Holdings of more than 20%

The charitable company holds more than 20% of the share capital in the following company:

Country of Shares held
Company incorporation Class %
The Coeliac Trading Company Ltd England & Wales Ordinary 100

The principal activity of The Coeliac Trading Company Limited (Company number 02856981) is to raise funds on a commercial basis for Coeliac UK (Limited by Guarantee), a registered charity. The address of the registered office is Artisan, Hillbottom Road. Sands Industrial Estate, High Wycombe, Buckinghamshire, HP12 4HJ.

The aggregate amount of capital and reserves and the results of this undertaking for the year ended 31 December 2023 were:

The Coeliac Trading Company Ltd

Profits to
reserves for
Capital the year
£ £
2 -

During 2023 the Trading Company proposed to donate its entire profits and reserves of £123,360 (2022: £2,655) to Coeliac UK. The profits are net of income and expenditure totalling £250,132 (2022: £290,203) and £240,750 (2022: £287,548) respectively. Additionally, the company made a surplus on disposal of its operations to Coeliac UK totalling £113,798.

Current asset investments and deposits held relate exclusively to cash deposit accounts and amounted to £nil (2022: £623,357) as shown on the balance sheet.

Page 37

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

12 Debtors

2023
2022
£
£
Trade debtors
142,846
122,290
Income tax and VAT recoverable
75,124
-
Amounts owed by group undertakings
-
-
Prepayments and accrued income
1,386,720
885,809
1,604,690
1,008,099
13 Creditors: amounts falling due within one year
2023
2022
£
£
Grants payable
136,080
194,230
Trade creditors
372,192
286,136
Other tax and social security
52,940
11,448
Accruals
307,856
122,112
Deferred income
503,204
523,904
1,372,272
1,137,830
Deferred income - Charity
At 1 January 2023
Released in 2023
Membership, licencing, Lottery and sponsorship income received in advance
At 31 December 2023
14 Provision for liabilities and charges - Group and Charity
At 1 January 2023
Charged for the year
At 31 December 2023
Group
Group		 2023
2022
£
£
142,846
87,411
75,124
-
111,904
238,348
1,386,720
885,809
1,716,594
1,211,568
2023
2022
£
£
136,080
194,230
372,192
276,495
52,940
2,571
307,856
117,062
503,204
490,481
1,372,272
1,080,839
2023
2022
£
£
490,481
456,905
(467,545)
(401,470)
480,265
435,046
503,201
490,481
£
40,000
(40,000)
-
Charity
Charity		 2023
2022
£
£
142,846
87,411
75,124
-
111,904
238,348
1,386,720
885,809
1,716,594
1,211,568
2023
2022
£
£
136,080
194,230
372,192
276,495
52,940
2,571
307,856
117,062
503,204
490,481
1,372,272
1,080,839
2023
2022
£
£
490,481
456,905
(467,545)
(401,470)
480,265
435,046
503,201
490,481
£
40,000
(40,000)
-
Charity
Charity
1,080,839
2022
£
456,905
(401,470)
435,046
490,481

The brought forward provision related to dilapidations costs payable at the end of the parent charity and group's tenancy at its previous address which concluded in the year.

Page 38

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

15 Designated funds - Group and Charity

Research (Innovate)
Research Fund
Local voluntary support groups
Research (Innovate)
Research Fund
Local voluntary support groups		 Balance at
01-Jan-23
2,314
10,194
85,783
98,291
Balance at
01-Jan-22
2,314
10,194
81,058
93,566		 Incoming
-
2,314
6,568
8,882
Incoming
-
-
32,469
32,466		 Outgoing
(2,314)
(103)
(11,533)
(13,950)
Outgoing
-
-
(27,744)
(27,741)		 Balance at
31-Dec-23
-
12,405
80,818
93,223
Balance at
31-Dec-22
2,314
10,194
85,783
98,291

Research, including Innovate

Income to be used for funding medical research into Coeliac disease and dermatitis herpetiformis, designated by the Board from unrestricted funds.

Local voluntary support groups

The collective funds held and administered by Volunteer Groups, representing their working funds.

Page 39

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

16 Restricted funds - Group and Charity

Research Fund
Daily newspaper advert for
Awareness Week
Awareness Week
Care System campaigns
Membership Helpline
Diagnosis TV Advert
Diagnosis Life Channel NHS
Pharmacy Packs
Diagnosis campaign
Events for children with
CD and families
Digital Campaign
Gluten Ataxia
Sponsored Dissertations
Research Fund
Daily newspaper advert for
Awareness Week
Care System campaigns
Membership Helpline
Diagnosis TV Advert
Diagnosis Life Channel NHS
Pharmacy Packs
Diagnosis campaign
Events for children with
CD and families
Digital Campaign
Gluten Ataxia
Sponsored Dissertations		 Balance at
01-Jan-23
499,056
1,529
-
17
165
2,947
2,014
1,075
37,732
5,036
2,014
7,770
7,500
566,855
Balance at
01-Jan-22
277,208
1,477
17
140
2,926
2,000
1,067
119,767
5,000
2,000
7,578
-
419,180		 Incoming
91,674
-
35,028
-
1
-
-
-
-
-
-
34,500
-
161,203
Incoming
230,576
41
-
24
-
-
-
27,778
-
-
137
-
258,557		 Investment
Outgoing
losses
(97,980)
(526)
-
(41)
(59,809)
-
-
(17)
-
-
(2,947)
-
(2,014)
-
-
(2)
8,390
(240)
-
(9)
(2,014)
-
-
(14)
-
-
(156,374)
(851)
Investment
Outgoing
gains/(losses)
-
(1,229)
-
11
-
-
-
1
-
21
-
14
-
8
(110,679)
866
-
36
-
14
-
55
-
-
(110,679)
(203)		 Transfer of
funds
-
-
24,782
-
-
-
-
-
(24,782)
-
-
-
-
-
Transfer of
funds
(7,500)
-
-
-
-
-
-
-
-
-
-
7,500
-		 Balance at
31-Dec-23
492,224
-
1,488
1
-
166
-
-
1,073
21,100
-
5,027
-
42,256
7,500
570,833
Balance at
31-Dec-22
499,056
1,529
17
165
2,947
2,014
1,075
37,732
5,036
2,014
7,770
7,500
566,855

Page 40

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

16 Restricted funds - Group and Charity

The principal purposes for the above restricted funds were as follows:

Research

Income received to be used solely for funding medical research into coeliac disease and dermatitis herperiformis (DH).

Local support

The collective funds held and administered by Volunteer Groups.

Daily newspaper advert for Awareness Week

Donations towards an advertisement to be placed in a major national newspaper during Awareness Week to raise the profile of Coeliac disease.

Care System campaign

Campaign to improve awareness in the care system.

Membership Helpline

Funding for ongoing costs of providing the Coeliac UK Helpline.

Diagnosis TV Advert

TV advertising campaign to improve diagnosis rates for Coeliac disease.

Diagnosis Life Channel NHS

Advertising campaign for patients via Life Channel in GP surgeries to raise awareness of Coeliac disease.

Pharmacy packs

Donations towards production of pharmacy information packs.

Digital Campaign

Donations toward developing our digital communication materials

Gluten Ataxia

Income to fund a project to achieve an earlier diagnosis for those with Gluten Ataxia.

Events for children with CD and families

Funds to be used by Coeliac UK for events to benefit coeliac children and their families.

Diagnosis Campaign

Funds have been granted to pay for the development of campaign materials to promote diagnosis of Coeliac disease in children in support of ongoing activities regarding awareness and education on Coeliac disease.

Awareness Week

Funds have been granted to support the Awareness week campaign of Coeliac disease in support of ongoing activities regarding awareness and education on Coeliac disease.

Sponsored Dissertations

Funds to be used by Coeliac UK to sponsor students' dissertations aimed at the advancement of awareness and research related to Coeliac disesase.

Page 41

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

17 Analysis of net assets between funds - Charity and group

Analysis of net assets between funds - Charity and group
Intangible assets
Tangible assets
Investments*
Net current assets less provisions for liabilities and charges		 Unrestricted
funds
2023
115,172
156,996
982,580
837,903
2,092,651		 Designated
funds
2023
-
-
-
93,223
93,223		 Restricted
funds
2023
-
-
-
570,833
570,833		 Total
2023
115,172
156,996
982,580
1,501,960
2,756,708
Intangible assets
Tangible assets
Investments
Net current assets less provisions for liabilities and charges		 Unrestricted
funds
2022
105,264
28,568
323,848
1,480,747
1,938,427		 Designated
funds
2022
-
-
-
98,291
98,291		 Restricted
funds
2022
-
-
-
566,855
566,855		 Total
2022
105,264
28,568
323,848
2,145,893
2,603,573

18 Lease commitments - Charity and group

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and five years
More than five years		 2023
2022
£
£
76,688
86,295
306,753
5,103
63,798
-
447,239
91,398
Land and buildings		 2023
2022
£
£
2,979
2,991
9,772
3,132
-
-
12,751
6,123
Office equipment		 2023
2022
£
£
2,979
2,991
9,772
3,132
-
-
12,751
6,123
Office equipment
6,123

19 Voluntary help

The charity had extra support from 250 volunteers in 2023 (2022: 370). The benefit of their contribution is not reflected in the in the financial statements.

20 Related party transactions

Coeliac UK holds 100% of the share capital of The Coeliac Trading Copmpany Limited. Details of transactions in the year and balances at the year end are detailed in note 11.

There were no other related party transactions in the reporting period that require disclosure.

Page 42

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

21 Pension commitments

The estimated pension deficit as at 31 December 2023 is £815 (31 December 2022: £1,533 ). This is in accordance with the most recent independent valuation performed on 30 September 2020. Under the new recovery plan, from 1 April 2023 the deficit contributions that are required from Coeliac UK are £772 a year, payable in monthly instalments of £64.32. These payments do not increase.

The deficit contributions agreed between the company and scheme at the yearend date are as follows:

Year Amount
1 772
2 64

The present value of the future provision for Coeliac UK is calculated as follows:

2023 2022
Provision at the start of the period 1,533 2,653
Discount factor interest expense 55 23
Deficit contribution paid (772) (1,086)
Remeasurement - impact of change in assumptions (1) (57)
Provision at end of period 31 December 815 1,533

The current deficit of £815 is being paid at an immaterial amount to the charity on an annual basis, this deficit would only fall due in its entirety should the charity decides to withdraw from the scheme, the Board of Trustees currently have no plans short or long term to withdraw from this scheme.

22 Reconciliation of net income/(expenditure) for the reporting period (as per the SOFA)

Net income/(expenditure) for the reporting period (as per the SOFA)
Adjustments for:
Amortisation and depreciation charges
(Gains)/losses on investments
Dividends from investments
Bank interest
Increase in debtors
Increase/(decrease) in creditors
Other gains/losses
Net cash provided by operating activities		 2023
£
153,135
66,866
(23,947)
(24,454)
(40,545)
(596,591)
194,442
614
(270,481)		 2022
£
522,675
46,496
16,152
(2,099)
(14,833)
(552,318)
(16,192)
-
(119)

Page 43

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements
23 Analysis of cash and cash equivalents
Cash in hand
Notice deposits (less than 3 months)
Total cash and cash equivalents
Analysis of changes in net debt
Cash
Cash equivalents		 Balance at
01-Jan-23
1,202
2,314,421
2,315,623		 2023
£
240
1,269,262
1,269,502
Cash flows
(962)
(1,045,159)
(1,046,121)		 2022
£
1,202
2,314,421
2,315,623
Balance at
31-Dec-23
240
1,269,262
1,269,502

Page 44